Contents

Search

neuroendocrine carcinoma

Pathology: - well-differentiated neuroendocrine carcinomas are indolent [1] - most express somatostatin receptors [2] Radiology: - serial imaging with CT or MRI with contrast for well-differentiated neuroendocrine carcinomas [1] Management: - well-differentiated neuroendocrine carcinomas may be observed [1] - hepatic artery embolization used to treat localized neuroendocrine carcinomas of the liver [1] - high-grade neuroendocrine carcinoma of unknown primary should be treated with - platinum-based chemotherapy [1] - metastatic neuroendocrine tumors may be treated with systemic chemotherapy, or peptide receptor radionuclide therapy* [3] * a radionuclide linked to a somatostatin analogue targets somatostatin receptor- expressing neuroendocrine tumors

Interactions

disease interactions

Related

malignant endocrine neoplasm

Specific

medullary thyroid carcinoma Merkel cell carcinoma (neuroendocrine cancer of skin, trabecular cancer) small cell carcinoma of the lung (SCLC, oat cell carcinoma)

General

carcinoma neuroendocrine neoplasm

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 2018.
  2. Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well- differentiated neuroendocrine tumors. Nat Clin Pract Oncol. 2009 Mar;6(3):143-52. PMID: 19190591
  3. Kipnis ST, Hung M, Kumar S et al Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. JAMA Netw Open. 2021;4(3):e212274 March 23 PMID: 33755166 Free article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777778